Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

This study has been completed.
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01195662
First received: September 3, 2010
Last updated: April 28, 2014
Last verified: April 2014
Results First Received: February 7, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator);   Primary Purpose: Treatment
Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin
Drug: Placebo matching Dapagliflozin

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in Double-Blind Period who were randomized and treated with at least one dose of double-blind study medication.

Reporting Groups
  Description
Placebo Matching Dapagliflozin Placebo matching dapagliflozin: Tablets, Oral, 0 mg, once daily, Up to 12 weeks. Non-investigational medications used in this study were antidiabetic drug(s), including oral antidiabetic drugs and insulin, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and an additional antihypertensive drug. All non-investigational medications were commercially available and were not supplied by the Sponsor.
Dapagliflozin 10 mg Dapagliflozin: Tablets, Oral, 10 mg, once daily, Up to 12 weeks. Non-investigational medications used in this study were antidiabetic drug(s), including oral antidiabetic drugs and insulin, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and an additional antihypertensive drug. All non-investigational medications were commercially available and were not supplied by the Sponsor.
Dagagliflozin 5 mg (Arm Discontinued With Amendment 8) Dapagliflozin: Tablets, Oral, 5 mg, once daily, Up to 12 weeks. This arm discontinued with implementation of Amendment 8 to the protocol (1 November 2011). Study continued to enroll participants in other 2 arms post Amendment 8. Non-investigational medications used in this study were antidiabetic drug(s), including oral antidiabetic drugs and insulin, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and an additional antihypertensive drug. All non-investigational medications were commercially available and were not supplied by the Sponsor.
Total Total of all reporting groups

Baseline Measures
    Placebo Matching Dapagliflozin     Dapagliflozin 10 mg     Dagagliflozin 5 mg (Arm Discontinued With Amendment 8)     Total  
Number of Participants  
[units: participants]
  224     225     133     582  
Age, Customized  
[units: participants]
       
Less than (<) 65 years     198     198     118     514  
Greater than, equal (>=) to 65 and < 75 years     25     23     14     62  
>= 75 years     1     4     1     6  
Gender  
[units: participants]
       
Female     95     107     52     254  
Male     129     118     81     328  
Race/Ethnicity, Customized [1]
[units: participants]
       
White     157     160     84     401  
Black or African American     17     19     9     45  
Asian     38     34     36     108  
Other Race     12     12     4     28  
Ethnicity Hispanic/Latino     41     47     21     109  
Ethnicity Not Hispanic/Latino     40     38     16     94  
Ethnicity Not Reported     143     140     96     379  
Body Mass Index (BMI) [2]
[units: participants]
       
< 25 kg/m^2     21     17     9     47  
>=25 kg/m^2     203     208     124     535  
>=27 kg/m^2     179     178     101     458  
>=30 kg/m^2     147     141     73     361  
Hypertension Medication [3]
[units: participants]
       
Thiazide or thiazide-like diuretics, no insulin     94     95     54     243  
Calcium channel and beta blockers, no insulin     114     112     79     305  
Thiazide or thiazide-like diuretics, insulin     5     6     0     11  
Calcium channel and beta blockers, insulin     11     12     0     23  
[1] Ethnicity was collected and summarized only for USA participants.
[2] BMI is measured by weight in kilograms (kg) divided by height in meters (m) squared (kg/m^2). Less than (<); Greater than, equal to (>=).
[3]

The following categories served as a randomization stratification factor:

category 1: thiazide or thiazide-like diuretics and no insulin category 2: calcium channel blockers, beta blockers, central alpha adrenergic agonist or alpha adrenergic blockers and no insulin category 3: thiazide or thiazide-like diuretics and insulin category 4: calcium channel blockers, beta blockers, central alpha adrenergic agonist or alpha adrenergic blockers and insulin




  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants   [ Time Frame: Baseline to Week 12 ]

2.  Primary:   Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) for 12 Week Double-Blind Treatment Period - Randomized Participants   [ Time Frame: Baseline to Week 12 ]

3.  Secondary:   Adjusted Mean Change From Baseline in 24-hour Ambulatory Systolic Blood Pressure at Week 12 Last Observation Carried Forward (LOCF)   [ Time Frame: Baseline, Week 12 ]

4.  Secondary:   Adjusted Mean Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 12 Week Double-Blind Treatment Period - Randomized Participants   [ Time Frame: Baseline to Week 12 ]

5.  Secondary:   Adjusted Mean Change From Baseline in 24-hr Ambulatory Diastolic Blood Pressure at Week 12 (LOCF)   [ Time Frame: Baseline, Week 12 ]

6.  Secondary:   Adjusted Mean Change From Baseline in Serum Uric Acid at Week 12 in Double-Blind Treatment Period - Randomized Participants   [ Time Frame: Baseline, Week 12 ]

7.  Secondary:   Number of Participants With Deaths,Serious Adverse Events (SAEs), Adverse Events (AEs), Hypoglycemia Events, Discontinuation Due to AEs, SAEs and Hypoglycemia, During the 12 Week Double Blind Period, Including Data After Rescue   [ Time Frame: Baseline to last dose of 12 weeks of double blind medication plus 30 days if SAE or plus 4 days if AE/hypoglycemic event ]

8.  Secondary:   Number of Participants With Marked Chemistry Laboratory Abnormalities in 12 Week Double Blind Treatment Period, Including Data After Rescue   [ Time Frame: Baseline (Day 1) to last dose double blind medication (Week 12) plus 4 days ]

9.  Secondary:   Number of Participants With Elevated Liver Laboratory Tests in Participants Treated With Double Blind 10 mg Dapagliflozin or Placebo , Including Data After Rescue   [ Time Frame: Baseline (Day 1) to last dose double blind medication (Week 12) Plus 30 days ]

10.  Secondary:   Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 12 (LOCF), Including Data After Rescue   [ Time Frame: Baseline, Week 12 ]

11.  Secondary:   Proportion of Participants With Orthostatic Hypotension at Baseline and Week 12, Including Data After Rescue   [ Time Frame: Baseline (Day 1), Week 12 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Totality of data from dapagliflozin development program as of 1 NOV 2011 showed 10 mg dapagliflozin dose provided optimal efficacy, was safe and well tolerated for the general Type 2 diabetes population, allowing the 5 mg arm to be discontinued.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Bristol-Myers Squibb Study Director
Organization: Bristol-Myers Squibb
e-mail: Clinical.Trials@bms.com


No publications provided


Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01195662     History of Changes
Other Study ID Numbers: MB102-077 ST, 2010-019798-13
Study First Received: September 3, 2010
Results First Received: February 7, 2014
Last Updated: April 28, 2014
Health Authority: United States: Food and Drug Administration
Mexico: Secretaria de Salud
Australia: Department of Health and Ageing Therapeutic Goods Administration
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Hungary: National Institute of Pharmacy
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Russia: Ministry of Health of the Russian Federation
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Denmark: Ministry of Health